8-K: Vistagen Receives U.S. Patent for AV-101 to Treat Neuropathic Pain, Bolstering Collaborative Development Potential

Vistagen Therapeutics has been granted a U.S. patent for its non-opioid product candidate, AV-101, for the treatment of neuropathic pain, extending patent protection to at least 2034.

Summary

• Vistagen Therapeutics announced that the U.S. Patent and Trademark Office granted a patent for AV-101, an oral non-opioid product candidate, for treating neuropathic pain.
• The patent extends until at least 2034 and is part of Vistagen's global patent portfolio for AV-101's manufacturing methods and therapeutic uses related to the NMDA receptor.
• Preclinical data showed AV-101 has robust antinociceptive effects similar to gabapentin but with a better side effect profile.
• Clinical Phase 1 studies indicated that oral AV-101 was well-tolerated, with no significant difference in adverse events compared to placebo.
• Vistagen plans to seek strategic collaborations to advance the clinical development and commercialization of AV-101 for disorders involving the NMDA receptor, particularly pain and dyskinesias.

Sentiment

Score: 8

Explanation: The announcement of a new patent is generally positive, especially in the biopharmaceutical industry. The positive preclinical and clinical data further contribute to a favorable outlook for AV-101.

Positives

• The U.S. patent grant strengthens Vistagen's position for potential collaborative development and commercialization of AV-101.
• Preclinical data suggests AV-101 has a better side effect profile compared to gabapentin.
• Clinical data indicates AV-101 is well-tolerated.
• AV-101 has Fast Track designation from the FDA for neuropathic pain and adjunctive treatment of major depressive disorder.

Risks

• The success of AV-101 depends on securing collaborative support for continued clinical development.
• Delays in clinical trials and fluctuating costs of materials could impact development.
• There is no guarantee that AV-101 will replicate past preclinical studies and/or clinical trials, complete ongoing or future clinical trials in part or at all, receive regulatory approval or be commercially successful.

Future Outlook

Vistagen plans to seek potential strategic collaborations to further advance the clinical development and commercialization of AV-101 for disorders involving the NMDA receptor, particularly pain and dyskinesias.

Management Comments

• Shawn Singh, President and Chief Executive Officer of Vistagen, stated that the new patent advances their AV-101 portfolio and significantly strengthens their position for potential collaborative development and commercialization.
• Shawn Singh mentioned they look forward to identifying potential partnering opportunities for AV-101 as a non-opioid alternative for pain, as well as dyskinesias and other neurological disorders.

Industry Context

The development of non-opioid alternatives for pain management is a significant area of focus in the pharmaceutical industry due to the opioid crisis. AV-101's potential as a non-opioid treatment for neuropathic pain aligns with this trend.

Comparison to Industry Standards

• AV-101 is being compared to gabapentin and pregabalin, which are approved to treat neuropathic pain.
• The preclinical studies compare AV-101 to pregabalin in the Chung ligation model of pain, an accepted gold standard preclinical model for chronic neuropathic pain caused by nerve damage.
• The company believes that AV-101's active metabolite, 7-Cl-KYNA, is not an ion channel blocker, unlike classic channel-blocking NMDA receptor antagonists such as ketamine and amantadine, which the Company believes is the reason for the compounds comparatively improved safety and tolerability profile.

Stakeholder Impact

• Shareholders may react positively to the patent news.
• Patients suffering from neuropathic pain may benefit from the development of AV-101 as a non-opioid alternative.
• Potential partners may be interested in collaborating with Vistagen on AV-101's development and commercialization.

Next Steps

• Vistagen plans to seek potential strategic collaborations to further advance the clinical development and commercialization of AV-101.

Key Dates

Keywords

AV-101, neuropathic pain, patent, Vistagen, NMDA receptor, pharmaceutical, biopharmaceutical